TY - JOUR
T1 - Mechanism of anti-angiogenic property of gold nanoparticles
T2 - Role of nanoparticle size and surface charge
AU - Arvizo, Rochelle R.
AU - Rana, Subinoy
AU - Miranda, Oscar R.
AU - Bhattacharya, Resham
AU - Rotello, Vincent M.
AU - Mukherjee, Priyabrata
N1 - Funding Information:
Supported by NIH CA135011 , CA136494 and UTMD-1 grants (P.M.) and GM GM077173 (V.M.R.).
PY - 2011/10
Y1 - 2011/10
N2 - Discovering therapeutic inorganic nanoparticles (NPs) is evolving as an important area of research in the emerging field of nanomedicine. Recently, we reported the anti-angiogenic property of gold nanoparticles (GNPs): It inhibits the function of pro-angiogenic heparin-binding growth factors (HB-GFs), such as vascular endothelial growth factor 165 (VEGF165) and basic fibroblast growth factor (bFGF), etc. However, the mechanism through which GNPs imparts such an effect remains to be investigated. Using GNPs of different sizes and surface charges, we demonstrate here that a naked GNP surface is required and core size plays an important role to inhibit the function of HB-GFs and subsequent intracellular signaling events. We also demonstrate that the inhibitory effect of GNPs is due to the change in HB-GFs conformation/configuration (denaturation) by the NPs, whereas the conformations of non-HB-GFs remain unaffected. We believe that this significant study will help structure-based design of therapeutic NPs to inhibit the functions of disease-causing proteins. From the Clinical Editor: In this landmark paper by Arvizo and colleagues, the angiogenesis inhibitor effects of gold nanoparticles were investigated as the function of size and charge. This study will pave the way to the development of therapeutic NPs that inhibit the functions of pathogenic proteins.
AB - Discovering therapeutic inorganic nanoparticles (NPs) is evolving as an important area of research in the emerging field of nanomedicine. Recently, we reported the anti-angiogenic property of gold nanoparticles (GNPs): It inhibits the function of pro-angiogenic heparin-binding growth factors (HB-GFs), such as vascular endothelial growth factor 165 (VEGF165) and basic fibroblast growth factor (bFGF), etc. However, the mechanism through which GNPs imparts such an effect remains to be investigated. Using GNPs of different sizes and surface charges, we demonstrate here that a naked GNP surface is required and core size plays an important role to inhibit the function of HB-GFs and subsequent intracellular signaling events. We also demonstrate that the inhibitory effect of GNPs is due to the change in HB-GFs conformation/configuration (denaturation) by the NPs, whereas the conformations of non-HB-GFs remain unaffected. We believe that this significant study will help structure-based design of therapeutic NPs to inhibit the functions of disease-causing proteins. From the Clinical Editor: In this landmark paper by Arvizo and colleagues, the angiogenesis inhibitor effects of gold nanoparticles were investigated as the function of size and charge. This study will pave the way to the development of therapeutic NPs that inhibit the functions of pathogenic proteins.
KW - Angiogenesis
KW - Gold nanoparticles
KW - Protein conformation
KW - VEGF165
UR - http://www.scopus.com/inward/record.url?scp=80053180372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053180372&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2011.01.011
DO - 10.1016/j.nano.2011.01.011
M3 - Article
C2 - 21333757
AN - SCOPUS:80053180372
SN - 1549-9634
VL - 7
SP - 580
EP - 587
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 5
ER -